OT-401
Glaucoma
Phase 2Active
Key Facts
About Ocumension Therapeutics
A Chinese ophthalmic biotech developing innovative drug delivery technologies for eye diseases including dry eye, glaucoma, and retinal disorders.
View full company profileTherapeutic Areas
Other Glaucoma Drugs
| Drug | Company | Phase |
|---|---|---|
| PREZIA Glaucoma Implant | PolyActiva | Preclinical |
| MIGS Device System | Micropoint Biotechnologies | Commercial |
| INM-088 | InMed Pharmaceuticals | Preclinical |
| ANX007 | Annexon Biosciences | Phase 2 |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| hOTX2 | BrainEver | Discovery |
| Glaucoma Treatment | BVI Medical | Commercial |
| MediPrint Lens (Glaucoma) | MediPrint Ophthalmics | Phase 2b |
| Glaucoma Program | Broadwing Bio | Pre-clinical |
| MSC Exosomal Eye Serum | Vitti Labs | Pre-clinical |
| BTQ1902 | Betaliq | Phase 2 |
| TODDD™ Platform | Amorphex Therapeutics | Pre-clinical |